RED BLOOD CELLS iStock-860621344-min.jpg

Targeting Deadly Brain Cancer
Using Remote-Controlled Nanotechnology

We hold numerous patents and licenses to innovative technology, including nanoparticle scintillators, which can target and destroy with timed precision.

A message from our founder, John Clark

Global Cancer Technology (GCT) is an emerging biopharmaceutical company headquartered in San Diego, CA.

RED BLOOD CELLS iStock-860621344-min.jpg

Cutting Edge Technology

Nanoparticle technology enables us to attack disease with timed precision.

Dr. Ekokobe Fonkem.jpg

Dr. Ekokobe Fonkem, director of neuro-oncology and an associate professor and chair in the Department of Neurology at Barrow Neurological Institute.

It takes a team effort

In collaboration with world renowned researchers and institutions, including the Barrow Neurological Institute, the University of San Diego and more, we are developing innovative treatments to fight deadly diseases like COVID and cancer.


“Incurable diseases like glioblastoma, commonly called ‘brain cancer,’ impose a high degree of suffering in patients who have few to no options regarding treatment. Being part of a collaborative effort around the creative application of new technologies gives us hope for a better future for these patients.”

RED BLOOD CELLS iStock-860621344-min.jpg

Cancer Treatment

Global Cancer Technology has numerous patents and other IP that might lead to breakthroughs in cancer therapy. The company is partnering with highly acclaimed academic institutions such as UCSD and the Barrow Neurological Institute, along with industry leaders, to make these therapies available to patients as quickly as possible. Global Cancer Technology’s lead cancer technology is its remote-controlled cancer drug delivery platform.

Learn more about Global Cancer Technology's remote-controlled cancer drug delivery platform by clicking here.

RED BLOOD CELLS iStock-860621344-min.jpg

COVID-19 Nanoparticle Treatment

​The coronavirus is mutating uncharacteristically fast. New strains are 50-70% more transmissible. The "UK Variant" [B.1.1.7] is now in 45 countries. Two other variants, the "South Africa Variant" [B.1.351] and one recently identified in Brazil could render existing treatments ineffective. Scott Gottlieb, the former director of the FDA, stated: “The South Africa variant is very concerning right now because it does appear that it may obviate some of our medical countermeasures, particularly the antibody drugs.

GCT has developed a method that targets coronavirus with high specificity and binds irreversibly to the virus particles. Once bound, an ultra-low dose x-ray (about 400 times less than a typical chest x-ray) activates the nanoparticles bound to the virus. Activation causes a blast of ultra-violet to be emitted directly into the coronavirus which kills it with timed precision.

Learn more about Global Cancer Technology's COVID-19 nanoparticle treatment by clicking here.

RED BLOOD CELLS iStock-860621344-min.jpg

Help us develop these life-saving technologies.
Invest now.

Minimum Investment


Share Price

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.


Need more info before becoming an investor?

Following the close of an investment round last year at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment for both COVID-19 and cancer.

Subscribe to get notified of our progress.

Thanks for submitting!